What is PCRX stock price today?

Visit our real-time dashboard for the current PCRX stock price and live market data.

Is PCRX stock going up or down today?

PCRX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy PCRX stock now?

The decision to buy PCRX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is PCRX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for PCRX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is PCRX stock overvalued or undervalued?

PCRX currently trades at a P/E ratio of 174.15, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if PCRX is fairly priced.

What is PCRX's P/E ratio?

PCRX has a price-to-earnings (P/E) ratio of 174.15, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is PCRX's market cap?

PCRX (Pacira BioSciences, Inc.) has a market capitalization of $0.89 billion, making it a small-cap stock.

What is PCRX's price to book ratio?

PCRX trades at a price-to-book (P/B) ratio of 1.36, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does PCRX pay dividends?

PCRX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is PCRX's dividend yield?

PCRX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is PCRX stock a good long-term investment?

PCRX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is PCRX's revenue growth rate?

Revenue growth data for PCRX is available on our dashboard with detailed financial statement analysis.

Profitability metrics for PCRX are available on our dashboard with complete income statement analysis.

What are the risks of investing in PCRX?

Key risks for PCRX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does PCRX compare to its competitors?

Compare PCRX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize PCRX's performance and positioning.

What is PCRX's stock price target for 2026?

Visit our prediction page for AI-powered price targets for PCRX with bull, base, and bear case scenarios.

What do analysts say about PCRX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for PCRX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is PCRX's next earnings report?

PCRX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

PCRX - Pacira BioSciences, Inc.

NYSE * Healthcare * Drug Manufacturers - Specialty & Generic

$0.00

+$0.00 (+0.00%)

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. (PCRX) common stock

Price Chart

Loading chart...

PCRX Key Statistics

Market Cap

$890.84M

P/E Ratio

174.15

P/B Ratio

1.36

How PCRX Compares to Peers

PCRX trades at a premium valuation vs peers (highest P/E)

PCRX is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

N/A

of 0

Growth Rank

N/A

of 0

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
PCRX(This stock)	$890.84M	174.2	0%	0.0%	-
LLYEli Lilly	$991.62B	39.5	0%	0.0%	vs LLY
JNJJohnson &	$375.37B	17.4	0%	0.0%	vs JNJ
PFEPfizer Inc	$147.73B	19.8	0%	0.0%	vs PFE
MRKMerck &	$285.12B	32.5	0%	0.0%	vs MRK
ABBVAbbVie Inc	$334.34B	80.5	0%	0.0%	vs ABBV

Data Updated: July 17, 2026 at 1:35 PM EDT

Ready to invest in PCRX?

Commission-free trading available. Affiliate links.

PCRX Lician Score

10% confidence

5.0/10

Neutral

PCRX has a Lician Score of 5/10 (Average). Areas of concern: Growth.

value

5.0

growth

3.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates PCRXacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

PCRX Financial Snowflake

5-axis analysis across key investment dimensions

4.6/10

Neutral

5.0

Value

Valuation vs. sector peers

3.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for PCRX

Dashboard

Enter a ticker to analyze